Generate Biomedicines Holds $516.6M Cash, Advances GB-0895 Phase 3 and GB-4362
GENB•Generate Biomedicines ended Q1 with $516.6 million in cash, cash equivalents and marketable securities, reflecting $369.3 million net IPO proceeds, and anticipates funding operations into H1 2028. The company advanced GB-0895 into Phase 3 asthma trials, activated GB-4362 sites for mid-2026 dosing and plans GB-5267 dosing in H2 2026.
1. Clinical Pipeline Progress
In the first quarter of 2026, Generate Biomedicines advanced its clinical portfolio by initiating Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials for GB-0895 in severe asthma alongside a Phase 1b COPD study. The GB-4362 MMAE neutralizer program received FDA Fast Track designation, activated trial sites and expects first patient dosing in mid-2026, while GB-5267, a MUC16 armored CAR T collaboration with Roswell Park, is slated for patient dosing in the second half of 2026.
2. Financial Results
For the quarter ended March 31, 2026, Generate reported revenue of $7.2 million versus $8.8 million a year earlier. Research and development expenses rose to $57.8 million from $46.8 million, general and administrative expenses increased to $13.5 million from $10.1 million, and net loss widened to $61.7 million from $44.3 million.
3. Cash Position and Outlook
As of March 31, 2026, Generate held $516.6 million in cash, cash equivalents and marketable securities, up from $221.5 million at year-end, driven by $369.3 million in net IPO proceeds. Management believes this liquidity will support operations through mid-2028, though additional capital will be required for long-term funding.
